Vitamin-D related single nucleotide polymorphisms (SNPs) with p-values <0.05 and risk of pancreatic cancer from PanScan I-III (3,583 cases and 7,053 controls).

<p>^a After bonferroni correction (0.05/213) p-values < 0.0002 were considered significant</p><p>^b Odds ratios (ORs) were adjusted for age (≤50, 51–60, 61–70, 71–80, ≥81 years), sex, study, and population stratification by 5 eigenvectors for ethnic ancestry.</p><p>^c Odds ratios (ORs) are for the number of copies of the minor allele.</p><p>^d Phase refers to participation in PanScan I, II or III. For rs4668123 data was available only from PanScan phases II and III.</p><p>Vitamin-D related single nucleotide polymorphisms (SNPs) with p-values <0.05 and risk of pancreatic cancer from PanScan I-III (3,583 cases and 7,053 controls).</p

Pathway analysis for risk of pancreatic cancer and gene sets in the vitamin D pathway (3,583 cases and 7,053 controls)

<p>^aP-values account for number of SNPs within genes or within the overall pathway, but not for the total number of genes; Models were adjusted for age (≤50, 51–60, 61–70, 71–80, ≥81 years), sex, study and population stratification by 5 eigenvectors for ethnic ancestry.</p><p>Pathway analysis for risk of pancreatic cancer and gene sets in the vitamin D pathway (3,583 cases and 7,053 controls)</p

Hazard ratios for type 2 diabetes per risk allele for each of 49 SNPs and per standard deviation for additive genetic scores, adjusted for sex and centre: the InterAct study.

<p>Analyses are based on 18,890 participants with data available for the genetic score—8,245 incident cases and 11,133 sub-cohort members (includes 488 incident cases). All models are adjusted for sex and centre, and with age as the underlying time scale. For comparability, HRs for the four genetic scores are presented per SD, where the SD is estimated in the sub-cohort.</p

Cumulative incidence of type 2 diabetes (percent) by quartiles of the imputed, unweighted genetic risk score and strata of body mass index, waist circumference, physical activity, and Mediterranean diet score: the InterAct study.

<p>(A) BMI (red: <25 kg/m²; blue: 25 to <30 kg/m²; black: ≥30 kg/m²), (B) WC (red: <94 cm in men and <80 cm in women; blue: 94 to <102 cm in men and 80 to <88 cm in women; black: ≥102 cm in men and ≥88 cm in women), (C) physical activity (red: active; blue: moderately active; green: moderately inactive; black: inactive), and (D) Mediterranean diet score (red: 11–18; blue: 7–10; black: 0–6).</p

Baseline characteristics of the random sub-cohort participants in the InterAct study.

<p>Family history of diabetes was not ascertained in Italy, Spain, Heidelberg (Germany), and Oxford (UK) (excluded from these summaries): 7,226/5,719. WC and waist–hip ratio were not measured in Umeå (Sweden) (excluded from these summaries): 1,050/1,007. Weight at age 20 y was not ascertained in France, Spain, Florence (Italy), Ragusa (Italy), Turin (Italy), Netherlands, Heidelberg (Germany), and Umeå (Sweden) (excluded from these summaries): 9,462/7,692. Data from Denmark (<i>n = </i>2,164) are excluded from this table.</p

Hazard ratios for type 2 diabetes per standard deviation (4.4 alleles) increase in the imputed, unweighted genetic risk score within strata defined by sex, diabetes family history, body mass index, waist circumference, age, physical activity, and Mediterranean diet score: the InterAct study.

<p>Prentice-weighted Cox regression models are adjusted for age, sex, and centre. F, female; M, male; Med., Mediterranean.</p

Ten-year risks of pancreatic cancer (y-axis), by age, gender, and risk score percentile (x-axis).

<p>The risk score includes smoking history, heavy alcohol intake, BMI, history of diabetes, family history of pancreatic cancer, ABO genotype and three common genetic variants associated with pancreatic cancer.</p

Reclassification of lifetime risk of pancreatic cancer after adding genetic information to the risk model with both genetic and non-genetic covariates.

<p>Reclassification of lifetime risk of pancreatic cancer after adding genetic information to the risk model with both genetic and non-genetic covariates.</p

Participants' Characteristics, the PanScan Consortium.

<p>Participants' Characteristics, the PanScan Consortium.</p

Reclassification of lifetime risk of pancreatic cancer among cohort controls after adding genetic information to the risk model.

<p>Reclassification of lifetime risk of pancreatic cancer among cohort controls after adding genetic information to the risk model.</p